Cryptotanshinone Protects Against Acute Pulmonary Edema

Year 2023, Volume: 13 Issue: 2, 121 - 126, 18.09.2023

Ümit Yılmaz , Mehmet Demir

https://doi.org/10.26650/experimed.1308908

Abstract

Objective: Cryptotanshinone (CTS) is a compound with anti-inflammatory, anti-bacterial, anti-oxidative and anti-aggregant functions. We aimed to determine the effects of CTS on α-naphtilthiourea (ANTU)-induced acute pulmonary edema.
Materials and Methods: In this study, 4 groups (control, sham, ANTU and ANTU+CTS) were established from a total of 40 rats. The ANTU+CTS group received intraperitoneal CTS for seven days, and both ANTU and ANTU+CTS received an ANTU administration for the induction of peripheral effusion. Four hours after the ANTU administration, the rats were subjected to a forced swim test and were decapitated. Swimming times of rats, amount of pleural effusion (PE), lung weight (LW)/body weight (BW), and PE/BW ratios were determined.
Results: At the end of the experiment, PE was not detected in the lungs of control and sham group rats. It was determined that the PE, LW/ BW and PE/BW decreased statistically, while swimming time increased after acute pulmonary edema in the CTS group (p<0.05).
Conclusion: CTS showed a protective effect against acute pulmonary edema, which indicates that it may be used as a new therapeutic agent against pulmonary toxicity.

Keywords

Cryptotanshinone; α-naphthylthiourea, pulmonary edema, pleural effusion, swimming duration

References

• 1. Panjwani A, Salman MR. An uncommon cause of pleural effusion. Breathe (Sheff) 2019; 15(2): e84-e9. google scholar
• 2. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104(5): 1486-9. google scholar
• 3. Riedel M. Noncardiogenic pulmonary edema. Ceskoslovenska fysiologie 1996; 45(2): 112-9. google scholar
• 4. MacIver DH, Clark AL. The vital role of the right ventricle in the pathogenesis of acute pulmonary edema. Am J Cardiol 2015; 115(7): 992-1000. google scholar
• 5. Glaus T, Schellenberg S, Lang J. Cardiogenic and non cardiogenic pulmonary edema: pathomechanisms and causes. Schweiz Arch Tierheilkd 2010; 152(7): 311-7. google scholar
• 6. Rapin M, Lemaire F. Les oedemes pulmonaires non hemodynamiques [Non cardiogenic pulmonary edema]. Sem Hop 1979; 55(7-8): 331-4. google scholar
• 7. Alwi I. Diagnosis and management of cardiogenic pulmonary edema. Acta Med Indones 2010; 42(3): 176-84. google scholar
• 8. Wang Y-J, Liao C-Y, Kao C-W. Nursing assessment and management of patients with cardiogenic pulmonary edema. Hu Li Za Zhi 2012; 59(1): 24. google scholar
• 9. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer’s disease, across the blood-brain barrier. Curr Drug Metab 2007; 8(4): 365-78. google scholar
• 10. Kim SY, Moon TC, Chang HW, Son KH, Kang SS, Kim HP. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses. Phytother Res 2002; 16(7): 616-20. google scholar
• 11. Park IJ, Kim MJ, Park OJ, Park MG, Choe W, Kang I, et al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett 2010; 298(1): 88-98. google scholar
• 12. Lee WY, Liu KW, Yeung JH. Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 2009; 285(1): 46-57. google scholar
• 13. Jin DZ, Yin LL, Ji XQ, Zhu XZ. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur J Pharmacol 2006; 549(1-3): 166-72. google scholar
• 14. Chen Q, Zhuang Q, Mao W, Xu XM, Wang LH, Wang HB. Inhibitory effect of cryptotanshinone on angiogenesis and Wnt/beta-catenin signaling pathway in human umbilical vein endothelial cells. Chin J Integr Med 2014; 20(10): 743-50. google scholar
• 15. Tang S, Shen XY, Huang HQ, Xu SW, Yu Y, Zhou CH, et al. Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways. Inflammation 2011; 34(2): 111-8. google scholar
• 16. Zhang Q, Gan C, Liu H, Wang L, Li Y, Tan Z, et al. Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis. Phytother Res 2020; 34(10): 2685-96. google scholar
• 17. Zhang Y, Lu W, Zhang X, Lu J, Xu S, Chen S, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res 2019; 147: 104307. google scholar
• 18. Wang X, Wan W, Lu J, Zhang Y, Quan G, Pan X, et al. Inhalable cryptotanshinone spray-dried swellable microparticles for pulmonary fibrosis therapy by regulating TGF-beta1/Smad3, STAT3 and SIRT3 pathways. Eur J Pharm Biopharm 2022; 172: 177-92. google scholar
• 19. Tang Y, Chen Y, Chu Z, Yan B, Xu L. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2014; 723: 494-500. google scholar
• 20. Jiang Y, You F, Zhu J, Zheng C, Yan R, Zeng J. Cryptotanshinone Ameliorates Radiation-Induced Lung Injury in Rats. Evid Based Complement Alternat Med 2019; 2019: 1908416. google scholar
• 21. Markov AK, Causey AL, Didlake RH, Lemos LB. Prevention of alpha-naphthylthiourea-induced pulmonary edema with fructose-1,6-diphosphate. Exp Lung Res 2002; 28(4): 285-99. google scholar
• 22. Richter CP. The physiology and cytology of pulmonary edema and pleural effusion produced in rats by alpha-naphthyl thiourea (ANTU). J Thoracic Surg 1952; 23(1): 66-91. google scholar
• 23. Park OK, Choi JH, Park JH, Kim IH, Yan BC, Ahn JH, et al. Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage. Fitoterapia 2012; 83(8): 1666-74. google scholar
• 24. De Caro C, Raucci F, Saviano A, Cristiano C, Casillo GM, Di Lorenzo R, et al. Pharmacological and molecular docking assessment of cryptotanshinone as natural-derived analgesic compound. Biomed Pharmacother 2020; 126: 110042. google scholar
• 25. Bai T, Yang K, Qin C, Xu T, Yu X, Zhang J. Cryptotanshinone ameliorates renal ischaemia-reperfusion injury by inhibiting apoptosis and inflammatory response. Basic Clin Pharmacol Toxicol 2019; 125(5): 420-9. google scholar
• 26. Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 2012; 7(6): 1009-14. google scholar
• 27. Barton CC, Bucci TJ, Lomax LG, Warbritton AG, Mehendale HM. Stimulated pulmonary cell hyperplasia underlies resistance to alpha-naphthylthiourea. Toxicology 2000; 143(2): 167-81. google scholar
• 28. Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, et al. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J Pharmacol Exp Ther 2006; 317(3): 1285-94. google scholar
• 29. Chen L, Wang HJ, Xie W, YaoY, Zhang YS, Wang H. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Mol Med Rep 2014; 9(6): 2447-52. google scholar
• 30. Qi PF, Li YL, Liu XM, Jafari FA, Zhang XJ, Sung QL, et al. Cryptotanshinone suppresses non-small cell lung cancer via microRNA-146a-5p/EGFR axis. Int J Biol Sci 2019; 15(5): 1072-9. google scholar
• 31. Wang H, Zhang Y, Zhang Y, Liu W, Wang J. Cryptotanshinone inhibits lung cancer invasion via microRNA-133a/matrix metalloproteinase 14 regulation. Oncol Lett 2019; 18(3): 2554-9. google scholar
• 32. Cao L, Hong WP, Cai PH, Xu CC, Bai XP, Zhao ZX, et al. Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. Eur J Pharmacol 2021; 890: 173647. google scholar
• 33. Li J, Zheng M, Wang C, Jiang J, Xu C, Li L, et al. Cryptotanshinone attenuates allergic airway inflammation through negative regulation of NF-kappaB and p38 MAPK. Biosci Biotechnol Biochem 2020; 84(2): 268-78. google scholar
• 34. Wang C, Zheng M, Choi Y, Jiang J, Li L, Li J, et al. Cryptotanshinone attenuates airway remodeling by inhibiting crosstalk between tumor necrosis factor-like weak inducer of apoptosis and transforming growth factor beta 1 signaling pathways in asthma. Front Pharmacol 2019; 10: 1338. google scholar
• 35. Jeon SJ, Son KH, Kim YS, Choi YH, Kim HP. Inhibition of prostaglandin and nitric oxide production in lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the roots of Salvia miltiorrhiza bunge. Arch Pharm Res 2008; 31(6): 758-63. google scholar
• 36. Tang Y, Chen YL, Chu Z, Yan B, Xu LJ. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2014; 723: 494-500. google scholar
• 37. Zhang YT, Lu WT, Zhang XL, Lu J, Xu SW, Chen SR, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res 2019; 147 :104307. google scholar
• 38. Jiang YF, You FM, Zhu J, Zheng C, Yan R, Zeng JH. Cryptotanshinone ameliorates radiation-induced lung injury in rats. Evid Based Complement Alternat Med 2019; 2019: 1908416. google scholar
• 39. Wang XH, Wan W, Lu J, Zhang YT, Quan GL, Pan X, et al. Inhalable cryptotanshinone spray-dried swellable microparticles for pulmonary fibrosis therapy by regulating TGF-beta 1/Smad3, STAT3 and SIRT3 pathways. Eur J Pharm Biopharm 2022; 172: 177-92. google scholar